TL;DR
This case report details a novel approach to treating recurrent tracheal adenoid cystic carcinoma (TACC) using a Y-shaped airway stent loaded with Iodine-125 (¹²⁵I) seeds. The treatment demonstrated a promising 5-year follow-up with no signs of relapse, suggesting this method could be a safe and effective option for patients with this rare and challenging cancer.
What Problem Does This Paper Address?
Tracheal adenoid cystic carcinoma (TACC) is a rare malignancy of the respiratory tract that, despite its low-grade nature, is prone to local recurrence and distant metastasis. Current treatment options, primarily surgical resection and radiotherapy, are not always feasible due to extensive lesions, airway stenosis, or poor patient tolerance. Interventional bronchoscopy offers an alternative, but it often involves long treatment cycles, numerous complications, and a high recurrence rate. This paper addresses the challenge of managing recurrent TACC, particularly in cases where standard treatments are insufficient or have failed, by exploring an innovative brachytherapy-infused stent approach.
Methods
The core of this paper's innovation lies in the application of a Y-shaped, covered airway stent loaded with ¹²⁵I seeds. This approach integrates mechanical support for airway stenosis with localized radiotherapy.
Here's a breakdown of the methodology:
- Initial Treatment: The patient initially underwent interventional bronchoscopy, including tumor resection with an electric loop, argon plasma coagulation (APC), and cryotherapy.
- Recurrence Management: Following recurrence, the patient received a Y-shaped airway stent. This stent was specifically designed with a covering to safely house ¹²⁵I seeds.
- ¹²⁵I Seed Loading: The ¹²⁵I seeds (0.50 mCi each) were meticulously positioned within the stent's covering using specialized forceps. The number and distribution of seeds were planned using a treatment planning system (TPS) based on multiplanar 3D CT reconstructions, with a prescribed dose of 120 Gy to the planned target volume (PTV).
- Stent Implantation: The loaded stent was implanted under general anesthesia using a rigid bronchoscope.
- Stent Removal: The ¹²⁵I seed stent was intentionally removed after 5 months.
- Follow-up: The patient was monitored for 5 years post-implantation, with follow-up including chest CT scans and bronchoscopy.
The novelty lies in the combination of a covered Y-shaped stent specifically designed for ¹²⁵I seed delivery and its application in managing recurrent TACC, followed by a planned removal.
Datasets
Not discussed in the paper. The study is a case report focusing on a single patient's treatment and follow-up.
Key Insights and Ideas
- Dual-Action Stent: The ¹²⁵I seed-loaded stent offers a dual benefit: it mechanically supports the airway to alleviate stenosis and simultaneously delivers localized radiation therapy directly to the tumor site. This is particularly advantageous for difficult-to-reach or recurrent tumors.
- Targeted Brachytherapy: ¹²⁵I seeds provide a low-energy, short-range radiation source, allowing for precise targeting of the tumor while minimizing damage to surrounding healthy tissues. This is crucial in the delicate airway environment.
- Temporary Brachytherapy: The decision to remove the stent after 5 months is a significant aspect. This suggests that the ¹²⁵I seeds can provide a potent, short-term therapeutic effect, and the stent's mechanical support might not be needed indefinitely, potentially reducing long-term complications associated with permanent implants.
- Promising Long-Term Outcome: The 5-year follow-up showing no recurrence is a compelling result, especially given the challenging nature of recurrent TACC. This case provides strong evidence for the potential efficacy of this treatment modality.
Key Results
The primary result is the successful management of recurrent TACC in a single patient over a 5-year follow-up period.
- No Recurrence: The patient exhibited no signs of tumor recurrence or progression during the 5-year postoperative follow-up.
- Symptom Relief: The stent implantation effectively improved airway patency, as evidenced by the absence of respiratory symptoms like coughing and wheezing during the follow-up period.
- Procedure Tolerability: The patient tolerated the stent implantation and subsequent removal well, with no immediate complications such as chest pain, persistent cough, hemoptysis, mediastinal emphysema, fistula formation, or secondary pulmonary infection reported.
- 8-Year Survival: The report notes an 8-year survival duration for the patient, indicating a significant long-term benefit from this treatment approach.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Single Case Report: The most significant limitation is that this is a case report based on a single patient. The findings cannot be generalized without further studies.
- Need for Multicenter Studies: The authors emphasize the need for multicenter, prospective, large-sample randomized controlled studies to confirm the safety and efficacy of this treatment.
- Optimization of Stent Design and Protocol: Further research is required to improve the design and technology of ¹²⁵I seed airway stents. This includes standardizing the number, activity, and arrangement of ¹²⁵I particles within the stent.
- Optimal Removal Timing: The optimal timing for removing ¹²⁵I seed airway stents needs further investigation.
- Complication Monitoring: While this case had a favorable outcome, the authors highlight potential complications associated with ¹²⁵I seed stenting, including bleeding, airway perforation, chest pain, pneumothorax, mediastinal emphysema, and tracheoesophageal fistulas. Future research must rigorously monitor for and address these potential issues.
Summary updated